Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges
MedComm · 2024-11 · 5 (11)
DOI: 10.1002/mco2.766 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 09.11.2024. Verfasst von Lingyu Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Central Laboratory & Shenzhen Key Laboratory of Epigenetics and Precision Medicine for Cancers National Cancer Center/National Clinical Research Cent…. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 250 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Circulating tumor DNA (ctDNA) methylation, an innovative liquid biopsy biomarker, has emerged as a promising tool in early cancer diagnosis, monitoring, and prognosis prediction. As a noninvasive approach, liquid biopsy overcomes the limitations of traditional tissue biopsy. Among various biomarkers, ctDNA methylation has garnered significant attention due to its high specificity and early detection capability across diverse cancer types. Despite its immense potential, the clinical application of ctDNA methylation faces substantial challenges pertaining to sensitivity, specificity, and standardization. In this review, we begin by introducing the basic biology and common detection techniques of ctDNA methylation. We then explore recent advancements and the challenges faced in the clinical application of ctDNA methylation in liquid biopsies. This includes progress in early screening and diagnosis, identification of clinical molecular subtypes, monitoring of recurrence and minimal residual disease (MRD), prediction of treatment response and prognosis, assessment of tumor burden, and determination of tissue origin. Finally, we discuss the future perspectives and challenges of ctDNA methylation detection in clinical applications. This comprehensive overview underscores the vital role of ctDNA methylation in enhancing cancer diagnostic accuracy, personalizing treatments, and effectively monitoring disease progression, providing valuable insights for future research and clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Central Laboratory & Shenzhen Key Laboratory of Epigenetics and Precision Medicine for Cancers National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital Chinese Academy of M…
ORCID-Profile: Yingli Sun
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, L., & Sun, Y. (2024). Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges. MedComm, 5(11). https://doi.org/10.1002/mco2.766
Vancouver
Li L, Sun Y. Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges. MedComm. 2024;5(11). doi:10.1002/mco2.766
BibTeX
@article{Li2024,
author = {Li, Lingyu and Sun, Yingli},
title = {Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges},
journal = {MedComm},
year = {2024},
volume = {5},
number = {11},
doi = {10.1002/mco2.766}
}
EUVIMED